Echo IQ’s EchoSolv-AS decision-support software program for cardiology delivers vital potential advantages to hospital networks based on unbiased scientific presentation at prestigious New York Valves scientific convention.
NEW YORK, June 6, 2024 /PRNewswire/ — On the Structural Coronary heart Summit New York Valves earlier at the moment, Dr. Pedro Covas (Baylor Scott & White, The Coronary heart Hospital Plano TX) delivered the scientific presentation: AI-Powered Cardiac Ultrasound Improves Identification of Excessive-Threat Aortic Stenosis (Echo IQ).
Dr. Covas highlighted the unmet want for an AI system for aortic stenosis “ a type of coronary heart valve illness characterised by excessive charges of mortality when untreated. He revealed that the situation is underdiagnosed and undertreated worldwide, partly because of the complexity within the analysis of extreme aortic stenosis (together with low-flow states), and that there’s a want for help to enhance charges of analysis. As backed up by the analysis offered by Dr. Covas, Echo IQ makes use of synthetic intelligence to aide in figuring out a high-risk phenotype of aortic stenosis, to in the end assist with well timed analysis and therapy.
LEARN HOW ECHO IQ USES AI TO SUPPORT ENHANCED DISEASE DETECTION:
The unbiased analysis offered by Dr. Covas thought of whether or not synthetic intelligence might enhance accuracy and reproducibility of analysis of extreme aortic stenosis in a real-world hospital setting. To check this, Echo IQ’s know-how (EchoSolv) was utilized to the echocardiographic report knowledge of one in all Baylor Scott & White’s main tutorial coronary heart hospitals over a 7-month interval with a subset of the assessments adjudicated through complete picture assessment by knowledgeable cardiographers.
The findings confirmed EchoSolv to achieve success in figuring out extra sufferers vulnerable to aortic stenosis than human-only analysis. Particularly,
- EchoSolv precisely recognized 15% extra sufferers with extreme aortic stenosis than human-only analysis
- The place preliminary underdiagnosis occurred, sufferers have been discovered to have a “low flow” state of illness in 30% of instances (subsequently recognized by EchoSolv)
The analysis concluded that:
- Echo IQ’s know-how can mechanically determine aortic stenosis sufferers at-risk utilizing solely echocardiographic measurement knowledge.
- Echo IQ’s know-how has the potential to enhance diagnostic charges of extreme aortic stenosis, significantly in low movement states.
- There are necessary implications for much less specialised cardiology facilities, the place echocardiographers are more likely to profit probably the most from automated analysis of extreme AS.
Echo IQ Chief Medical Advisor, Professor David Playford mentioned: “This kind of independent research demonstrates exactly how Echo IQ’s artificial intelligence can help healthcare professionals identify patients with severe cases of aortic stenosis as well as those with significant risk of disease. Diagnosing aortic stenosis accurately, and in a timely fashion, is extremely complex and the findings shared by Dr. Covas show clearly how Echo IQ’s artificial intelligence can help improve clinical performance.”
About Echo IQ
Echo IQ makes use of synthetic intelligence for resolution help in structural coronary heart illness. The corporate’s first totally AI-enabled answer has been submitted for remaining FDA clearance. The corporate is headquartered in Sydney, Australia and is publicly listed on the Australian Securities Trade (ASX:EIQ). Don Fowler is President, Echo IQ USA, and relies in Austin, TX.
